Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …

Previously published guidelines for the diagnosis and management of primary immune
thrombocytopenia (ITP) require updating largely due to the introduction of new classes of …

Diagnosis and management of immune thrombocytopenic purpura (ITP) remain largely
dependent on clinical expertise and observations more than on evidence derived from …

Children with immune thrombocytopenia (ITP) rarely suffer from life-threatening bleeds (eg,
intracranial hemorrhage). In such settings, the combination of IV methylprednisolone (IVMP) …

Background The oral thrombopoietin receptor agonist eltrombopag is approved for treatment
of adults with chronic immune thrombocytopenia. In the PETIT trial, we aimed to investigate …

Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintains platelet counts
in adults with immune thrombocytopenia (ITP). In this first study of a thrombopoietic agent in …

Background The thrombopoietin receptor agonist romiplostim could be an effective
treatment in symptomatic children with persistent or chronic immune thrombocytopenia. We …

Immune thrombocytopenia (ITP) occurs with an incidence rate of 1.6 to 3.9 per 100,000
patient-years, which increases with age and has a slight female preponderance. ITP is …

Controversy exists regarding management of children newly diagnosed with immune
thrombocytopenic purpura (ITP). Drug treatment is usually administered to prevent severe …

Eltrombopag is currently the only US Food and Drug Administration–approved
thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia (ITP) …